CannPal Animal Therapeutics Limited (CP1) was a listed animal health Company developing innovative and naturally derived plant based therapeutic products for pets targeting the Endocannabinoid System.
The company had a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal merged with Auscann Group in 2021.
